Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab Combined With Apatinib Mesylate and Chemotherapy for Neoadjuvant Therapy in Limited-stage Small Cell Lung Cancer
NCT06483282Phase 2Recruiting
- Sponsor
- GeneFerm Biotechnology
- Start
- Jun 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of adebrelimab, Rivoceranib in small cell lung cancer (SCLC), sponsored by GeneFerm Biotechnology. Started Jun 2024; status: recruiting.
02
Drugs
adebrelimabRivoceranib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06483282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06483282.